Adverum Biotechnologies Inc. - נכסים נקיים למניה בודדת ADVM

The viability of Adverum Biotechnologies (ADVM) relies on the results of current trials, and the book value per share curve based on GURU.Markets data is illustrated on this chart, where the parameter has stabilized at -2.54. Retinal treatment developments and diversified patents serve as the foundation. Complex biologics and unique viral vectors ensure a high barrier to entry.

The success of Adverum Biotechnologies (ADVM) depends on the outcomes of gene therapy clinical trials, while significant cash reserves ensure financial stability. This metric is calculated as the difference between all assets and liabilities divided by the number of shares, allowing for an assessment of the real value of an investor's stake by analyzing the book value per share to determine the capital's defensive potential.